Thalidomide, although lowering TNF-α generation in cellular and animal studies, induced dose-limiting adverse events in a human Phase 2a AD study that precluded its administration at desired predetermined doses predicted to target CNS efficacy [82], and hence would be unlikely to be effective in human TBI. The gene discussed is TNF; the disease is Alzheimer disease.